CLL1 CAR T / Shanghai Yake Biotech - LARVOL DELTA

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies (ASH 2025) - P1/2 | "Background : CD7 chimeric antigen receptor (CAR) T-cell therapy has recently emerged as a promisingstrategy to induce remission of relapsed or refractory (R/R) CD7-positive hematologic malignancies...Lymphodepleting chemotherapy based with fludarabine,cyclophosphamide, and etoposide was administered, followed by infusion of CD7 CAR T cells at a dose of2×10⁶ cells/kg derived either from previous transplant or newly HLA-haploidentical donors...One patient had previously received CLL-1 CAR-T therapy.CD7 CAR T-cell products were successfully manufactured for all patients, which were sourced from newlyselected haploidentical donors in 15 cases (78.9%) and from prior transplant donors in 4 (21.1%)... This interim analyses further supported that this integrative strategy is safe and feasible inR/R CD7-positive malignancies, offering a promising therapeutic option—particularly for patientsineligible for conventional allo-HSCT."

CAR T-Cell Therapy • Clinical • P1 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7